Evidence map›Paper›PMID 36892511›Full record

ArticleActa dermato-venereologica2023

Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study.

Aino Vesikansa, Juha Mehtälä, Marko Pesu, Jaakko Aaltonen, Riikka Konttinen, Kaisa Tasanen, Laura Huilaja

Abstract read
In one paragraph

Article in Acta dermato-venereologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aino VesikansaMedEngine Oy, Helsinki, Finland. aino.vesikansa@medengine.fi.
Juha MehtäläMedEngine Oy, Helsinki, Finland.
Marko PesuGilead Sciences Finland Oy, Karhumäentie 3, 01530 Vantaa, Finland.
Jaakko AaltonenAbbVie Oy, Pasilan Asema Aukio 1, 00520 Helsinki, Finland.
Riikka KonttinenAbbVie Oy, Helsinki, Finland.
Kaisa TasanenDepartment of Dermatology and Medical Research Center, Oulu University Hospital; Research Group of Clinical Medicine, University of Oulu, Oulu, Finland.
Laura HuilajaDepartment of Dermatology and Medical Research Center, Oulu University Hospital; PEDEGO Research Unit, University of Oulu, Oulu, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic options for psoriasis vulgaris have changed during recent decades with the introduction of biologics. Few nationwide studies are available on psoriasis treatment patterns, and those from Finland predate the use of biologics. The aim of this retrospective, population-based registry study was to identify patients with psoriasis vulgaris and their treatment patterns in the secondary care setting in Finland. The study cohort included 41,456 adults with a diagnosis of psoriasis vulgaris in the public secondary healthcare setting from 2012 through 2018. Data on comorbidities, pharmacotherapy, and phototherapy were collected from nationwide healthcare and drug registries. Patients in the cohort had a wide range of comorbidities, with 14.9% having psoriatic arthritis. Treatment was based largely on topical and conventional systemic medications. Conventional medications were used by 28.9% of patients, and methotrexate was the most common option (20.9%). Biologics were used by 7.3% of patients, mostly as second- and third-line treatment. The use of conventional systemic medications, topical treatments, and phototherapy decreased after the initiation of biologics. This study of psoriasis vulgaris in Finland provides a framework for the development of future care practices.

Indexed as

Biological ProductsPsoriasisAdultFinlandHumansRegistriesRetrospective StudiesBiological Products

Identifiers

PMID36892511
PMCPMC10012470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.